%0 Journal Article
%T Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
%J -
%D 2019
%R https://doi.org/10.1038/s41416-019-0435-4
%X In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Intermittent therapy with 3-month breaks may be beneficial for patients¡¯ quality of life (QoL)
%U https://www.nature.com/articles/s41416-019-0435-4